ArriVent BioPharma: announces update from Phase 3 FURVENT trial

What happened ArriVent BioPharma, Inc. issued a press release on Oct 6, 2026 announcing an update from the Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant non-small cell lung cancer. The 8-K reports this disclosure under Item 7.01 and references the press release.

Key details

• The company filed the 8-K on Oct 6, 2026 under Item 7.01 (Regulation FD disclosure) and Item 8.01 (Other events).
• The press release announced an update from the Phase 3 FURVENT trial of firmonertinib for first-line EGFR exon 20 insertion mutant non-small cell lung cancer.
• The press release is filed as Exhibit 99.1 to the 8-K.

Why it may matter This filing reports a Regulation FD disclosure (Item 7.01) and other events (Item 8.01) consisting of a press release updating the Phase 3 FURVENT trial. The filing does not show why the insider traded or why the company acted.